Early overall morbidity (30 postoperative days) · patients with sigmoid diverticulitis
It is very uncertain whether laparoscopic changes early overall morbidity (30 postoperative days) compared with open surgery (very low certainty).
1 finding from 1 review
Toxicity ‐ early adverse events G3/4 · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
Combination chemotherapy probably leads to higher toxicity ‐ early adverse events G3/4 compared with single‐agent chemotherapy (moderate certainty).
1 finding from 1 review
Rate of spontaneous voiding recovery 1 week after surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time after surgery to post‐void residual volume of urine ≤ 50 mL (days)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (acute complication after surgery)
It is very uncertain whether suprapubic catheterisation changes adverse events (acute complication after surgery) compared with intermittent self‐catheterisation (very low certainty).
1 finding from 1 review
Post‐void residual urine volume (mL) at 1 month after surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Urinary tract infection
It is very uncertain whether suprapubic catheterisation changes urinary tract infections in the first month after surgery compared with intermittent self‐catheterisation (very low certainty).
1 finding from 1 review
Time after surgery to post‐void residual volume of urine ≤ 50 mL (days)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Post‐void residual urine volume (mL) at 1 month after surgery
1 finding from 1 review
Urinary tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of spontaneous voiding recovery 1 week after surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (survival until death from all causes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in overall survival (survival until death from all causes) compared with laparotomy (moderate certainty).
1 finding from 1 review
Recurrence‐free survival · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in recurrence free survival compared with laparotomy (moderate certainty).
1 finding from 1 review
Serious adverse events (range of outcomes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in serious adverse events (range of outcomes) compared with laparotomy (low certainty).
1 finding from 1 review
Postoperative pain: early pain (10 days postoperatively) VAS 0 to 10 Verbal reporting scale No pain‐mild pain‐moderate pain‐severe pain (converted to numerical scale (0 to 3, 3 to 6, 6 to 10)
2 findings from 1 review
Intervention not reported
Early postoperative non‐thrombotic complications · Individuals with peripheral arterial disease
The intervention showed no clear difference in early postoperative non‐thrombotic complications (high certainty).
1 finding from 1 review
Health‐related quality of life · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether laser ablation changes mortality at maximal compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Cancer‐related mortality at maximal · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether laser ablation changes cancer‐related mortality at maximal compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Serious adverse events (number of participants) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery
It is very uncertain whether laser ablation changes serious adverse events (number of participants) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review